Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12725524 | 0.73 | KDR (0.45) | KDRSIGMAR1 | |
| SCHEMBL6326828 | 0.71 | SIGMAR1 (0.44) | SIGMAR1TMEM97 | |
| SCHEMBL6766463 | 0.67 | TERT (0.34) | — | |
| SCHEMBL6320164 | 0.64 | PARP1 (0.40) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL7653299 | 0.63 | SIGMAR1 (0.63) | SIGMAR1 | |
| SCHEMBL5842762 | 0.59 | TERT (0.52) | SIGMAR1 | |
| SCHEMBL8363331 | 0.58 | L3MBTL1 (0.39) | — | |
| SCHEMBL261027 | 0.57 | SLC6A3 (0.43) | SIGMAR1 | |
| SCHEMBL14496908 | 0.56 | MAOA (0.39) | KDR | |
| SCHEMBL18706160 | 0.55 | CYP1A2 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861418-B2 | 4-aryl substituted indolinones | SUGEN, INC. (US) | 2005-03-01 | — | — | US | disclosed |
| US-20040157909-A1 | 4-Aryl substituted indolinones | SUGEN, INC. | 2004-08-12 | — | — | US | disclosed |
| US-6677368-B2 | 4-aryl substituted indolinones | SUGEN, INC. | 2004-01-13 | — | — | US | disclosed |
| EP-1349852-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | Sugen, Inc. (US) | 2003-10-08 | — | — | EP | disclosed |
| US-20030069297-A1 | 4-aryl substituted indolinones | SUGEN, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002055517-A2 | 4-(HETERO)ARYL SUBSTITUTED INDOLINONES | CUI JINGRONG (US) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069297-A1 | 4-aryl substituted indolinones | CDK5, CAMK4, TNK2 | KDR 819/4885SIGMAR1 2259/4885TMEM97 1879/4885 |
| US-20040157909-A1 | 4-Aryl substituted indolinones | CDK5, CAMK4, TNK2 | KDR 819/4885SIGMAR1 2259/4885TMEM97 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.